[1] Craig BM, Mitchell SA. Examining the Value of Menopausal Symptom Relief Among US Women. Value Health. 2016 Mar-Apr;19(2):158-66. doi: 10.1016/j.jval.2015.11.002. Epub 2015 Dec 4. PMID: 27021749.
[2] https://www.uptodate.com/contents/cannabis-use-epidemiology-pharmacology-comorbidities-and-adverse-effects
3] https://www.menopause.org/docs/default-source/press-release/cannabis-use-for-menopause-9-17-20.pdf
[4] Andrade AK, Renda B, Murray JE. Cannabinoids, interoception, and anxiety. Pharmacol Biochem Behav. 2019 May;180:60-73. doi: 10.1016/j.pbb.2019.03.006. Epub 2019 Mar 25. PMID: 30922834.
[5] M.P. Viveros, Eva M. Marco, Sandra E. File, Endocannabinoid system and stress and anxiety responses, Pharmacology Biochemistry and Behavior, Volume 81, Issue 2, 2005, pp 331-342, ISSN 0091-3057, https://doi.org/10.1016/j.pbb.2005.01.029.
[6] National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington (DC): National Academies Press (US); 2017 Jan 12. 12, Mental Health. Available from: https://www.ncbi.nlm.nih.gov/books/NBK425748/
[7] Fischer, B., Russell, C., Sabioni, P., van den Brink, W., Le Foll, B., Hall, W., Rehm, J. & Room, R. (2017). Lower-Risk Cannabis Use Guidelines (LRCUG): A Comprehensive Update of Evidence and Recommendations. American Journal of Public Health, 107(8). DOI: 10.2105/AJPH.2017.303818.
[8] https://doh.dc.gov/sites/default/files/dc/sites/doh/publication/attachments/Medical%20Cannabis%20Adverse%20Effects%20and%20Drug%20Interactions_0.pdf
[9] Tambaro, S., & Bortolato, M. (2012). Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives. Recent patents on CNS drug discovery, 7(1), 25–40. https://doi.org/10.2174/157488912798842269
[10] https://doh.dc.gov/sites/default/files/dc/sites/doh/publication/attachments/Medical%20Cannabis%20Adverse%20Effects%20and%20Drug%20Interactions_0.pdf
[11] Lu, H. C., & Mackie, K. (2016). An Introduction to the Endogenous Cannabinoid System. Biological psychiatry, 79(7), 516–525. https://doi.org/10.1016/j.biopsych.2015.07.028
[12] https://www.healthline.com/health/endocannabinoid-system
[13] Alger B. E. (2013). Getting high on the endocannabinoid system. Cerebrum : the Dana forum on brain science, 2013, 14.
[14] https://www.health.harvard.edu/blog/the-endocannabinoid-system-essential-and-mysterious-202108112569
[15a] Avery Michael C., Krichmar Jeffrey L. Neuromodulatory Systems and Their Interactions: A Review of Models, Theories, and Experiments. Frontiers in Neural Circuits 2017 Volume 11 DOI=10.3389/fncir.2017.00108
[15b] https://www.healthline.com/health/what-is-cannabis#components
[16] https://www.healthline.com/health/cbd-vs-thc
[17] Secades-Villa R, Garcia-Rodríguez O, Jin CJ, Wang S, Blanco C. Probability and predictors of the cannabis gateway effect: a national study. Int J Drug Policy. 2015;26(2):135-142. doi:10.1016/j.drugpo.2014.07.011
[18] https://nida.nih.gov/publications/research-reports/marijuana/letter-director
[19] Berenson A. (2019). Marijuana Is More Dangerous Than You Think. Missouri medicine, 116(2), 88–89.